Skip to main content
DERM
NASDAQ Life Sciences

Journey Medical 10-Q: Q3 Revenue $19.0M, Going-Concern Doubt Persists

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$4.9
Mkt Cap
$123.905M
52W Low
$4.25
52W High
$9.555
52W Position info
15% above low
Off High info
49% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

DERM sits 15% above its 52-week low of $4.25.

Summary

Journey Medical's Q3 10-Q confirms $19.0M revenue (up 8%) and $9.0M Emrosi sales, but keeps the going-concern warning, shows cash down to $22.3M, and moves $7.5M of term debt to short-term ahead of February 2027 principal payments.


Key Events · Earnings and Guidance · DERM

  • Q3 Revenue $19.0M, Emrosi Up 84%

    Total revenue was $19.0M versus $17.6M a year ago, with Emrosi contributing $9.0M versus $4.9M; Qobrexza fell to $5.6M from $7.4M.

  • Going-Concern Doubt Persists

    The 10-Q states substantial doubt exists about the company's ability to continue as a going concern for at least twelve months from issuance due to recurring losses.

  • Cash Falls to $22.3M

    Cash and equivalents were $22.3M at September 30, 2026 versus $24.1M at December 31, 2025; net cash used in operations was $2.3M for the nine months.

  • $7.5M Term Loan Now Short-Term

    Of the $25.0M SWK principal, $7.5M is classified short-term as quarterly principal payments of $2.5M begin February 2027, with $10.0M due in 2027 and $16.25M in 2028 including the exit fee.


Analysis · DERM · Life Sciences

The 10-Q confirms the Q3 numbers already released today but adds the full financial picture, and the key fact is that substantial doubt about the company's ability to continue as a going concern remains in the filing. Cash fell to $22.3M from $24.1M at year-end, and $7.5M of the $25.0M SWK term loan is now classified short-term because principal payments start February 2027. A $4.1M vendor settlement consumed cash in the quarter, with $1.7M above the prior accrual hitting SG&A. Revenue growth is real — Emrosi at $9.0M, up 84% — but the runway and the 2027 debt amortization are what determine whether the equity needs another raise.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, DERM was trading at $4.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $123.9M. The 52-week trading range was $4.25 to $9.56. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DERM - Latest Insights

DERM
Nov 12, 2026, 4:01 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.35
Real-time Price: $4.42 info
Change: +$0.0661 (+2%) info
Market Cap: $123.905M info
DERM
Aug 12, 2026, 4:40 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $6.99
Real-time Price: $4.42 info
Change: -$2.57 (-37%) info
Market Cap: $123.905M info
DERM
Aug 12, 2026, 4:11 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $6.61
Real-time Price: $4.42 info
Change: -$2.19 (-33%) info
Market Cap: $123.905M info
DERM
Aug 12, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.61
Real-time Price: $4.42 info
Change: -$2.19 (-33%) info
Market Cap: $123.905M info
DERM
May 13, 2026, 4:33 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.57
Real-time Price: $4.42 info
Change: -$1.15 (-21%) info
Market Cap: $123.905M info